News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
